Results 171 to 180 of about 272,115 (210)
Some of the next articles are maybe not open access.
2010
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability.
BANDELLO , FRANCESCO +1 more
openaire +4 more sources
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability.
BANDELLO , FRANCESCO +1 more
openaire +4 more sources
2021
In the current management of ROP, anti-VEGF drugs have a very significant role. These drugs can be used in ROP in different clinical situations: as a primary treatment for posterior ROP, for progressing cases after they have been previously treated either with a laser or with an anti-VEGF drug, and as an adjunct in ROP-related vitreoretinal surgery ...
Andrés Kychenthal, Paola Dorta
openaire +1 more source
In the current management of ROP, anti-VEGF drugs have a very significant role. These drugs can be used in ROP in different clinical situations: as a primary treatment for posterior ROP, for progressing cases after they have been previously treated either with a laser or with an anti-VEGF drug, and as an adjunct in ROP-related vitreoretinal surgery ...
Andrés Kychenthal, Paola Dorta
openaire +1 more source
Acta Ophthalmologica, 2014
AbstractThe diabetic macular edema (DME) related to visual loss, results mainly from changes in the affected blood‐retina barrier. VEGF, originally described as vascular permeability factor, is considered not only as a critical stimulus of retinal neovascularization but also as the primary inducer of increased vascular permeability involved in the ...
openaire +1 more source
AbstractThe diabetic macular edema (DME) related to visual loss, results mainly from changes in the affected blood‐retina barrier. VEGF, originally described as vascular permeability factor, is considered not only as a critical stimulus of retinal neovascularization but also as the primary inducer of increased vascular permeability involved in the ...
openaire +1 more source
Anti-VEGF and intraocular pressure
British Journal of Ophthalmology, 2011It is with great interest that I read the article by Good and associates1 on sustained elevation of intraocular pressure (IOP) after anti-vascular endothelial growth factor (VEGF) injections. Though several authors have observed raised IOP after intravitreal injections,2–6 this study assumes great importance since the authors have tried to identify ...
openaire +2 more sources
Anti-VEGF therapy for diabetic retinopathy
Vestnik oftal'mologii, 2021Diabetic retinopathy (DR) is one of the most severe complications of diabetes mellitus, its treatment involves specialists of different areas - endocrinologists, diabetes specialists, therapists, cardiologists, surgeons, anesthesiologists etc. For ophthalmologists the objective is to diagnose ocular pathological changes associated with diabetes ...
E S, Chekhonin +3 more
openaire +2 more sources
Therapeutic Anti-VEGF Antibodies
2008Vascular endothelial growth factor (VEGF-A) is a key cytokine in the development of normal blood vessels as well as the development of vessels in tumors and other tissues undergoing abnormal angiogenesis. Here, we review the molecular engineering of two humanized antibodies derived from a common mouse anti-VEGF antibody--bevacizumab, a full-length IgG1
S, Lien, H B, Lowman
openaire +2 more sources
Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets, 2020Background: Corneal neovascularization (CN) is a clue feature of different ocular pathological conditions and can lead to corneal edema and opacification with subsequent vision loss. Vascular endothelial growth factor (VEGF), which plays a key role in new vessels formation, proliferation and migration, was found to be up-regulated in these conditions.
Giannaccare, Giuseppe +6 more
openaire +3 more sources
Acta Ophthalmologica, 2012
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source
Anti-VEGF therapy in pituitary carcinoma
Pituitary, 2011We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken.
Ortiz, Leon D. +8 more
openaire +3 more sources
Acta Ophthalmologica, 2014
AbstractVascular endothelial growth factor A (VEGF‐A) was initially discovered as an endothelial cell‐specific growth factor, and current evidence suggests that it also plays numerous roles outside the vasculature, perhaps most significantly in the nervous system.
openaire +1 more source
AbstractVascular endothelial growth factor A (VEGF‐A) was initially discovered as an endothelial cell‐specific growth factor, and current evidence suggests that it also plays numerous roles outside the vasculature, perhaps most significantly in the nervous system.
openaire +1 more source